Olema Pharmaceuticals, Inc. (OLMA)

Market Cap	474.09M
Revenue (ttm)	n/a
Net Income (ttm)	-122.68M
Shares Out	57.26M
EPS (ttm)	-2.29
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	343,472
Open	8.71
Previous Close	8.72
Day's Range	8.12 - 8.79
52-Week Range	8.12 - 16.78
Beta	2.03
Analysts	Strong Buy
Price Target	27.00 (+226.09%)
Earnings Date	Nov 12, 2024

About OLMA

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 19, 2020
• Employees: 74
• Stock Exchange: NASDAQ
• Ticker Symbol: OLMA
• Website: https://olema.com

Analyst Forecast

According to 5 analysts, the average rating for OLMA stock is "Strong Buy." The 12-month stock price forecast is $27.0, which is an increase of 226.09% from the latest price.

Price Target

$27.0

(226.09% upside)

Analyst Consensus: Strong Buy